Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 22, 2016

Primary Completion Date

April 6, 2020

Study Completion Date

April 6, 2020

Conditions
Type 2 Diabetes
Interventions
DRUG

Dapagliflozin

Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.

DRUG

Dapagliflozin placebo

matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.

Trial Locations (42)

1023

Research Site, Budapest

4400

Research Site, Nyíregyháza

10467

Research Site, The Bronx

11410

Research Site, México, D.F.

14222

Research Site, Buffalo

19104

Research Site, Philadelphia

20010

Research Site, Washington D.C.

29615

Research Site, Greenville

32610

Research Site, Gainesville

33015

Research Site, Miami

33032

Research Site, Homestead

38116

Research Site, Memphis

38119

Research Site, Memphis

43205

Research Site, Columbus

44670

Research Site, Guadalajara

45116

Research Site, Zapopan

64460

Research Site, Monterrey

70300

Research Site, Ẕerifin

76550

Research Site, Lampasas

78503

Research Site, McAllen

80230

Research Site, Culiacán

84101

Research Site, Beersheba

91096

Research Site, Haifa

91120

Research Site, Jerusalem

97134

Research Site, Mérida

117036

Research Site, Moscow

194100

Research Site, Saint Petersburg

300011

Research Site, Timișoara

344022

Research Site, Rostov-on-Don

357500

Research Site, Pyatigorsk

410054

Research Site, Saratov

410169

Research Site, Oradea

426009

Research Site, Izhevsk

443079

Research Site, Samara

630087

Research Site, Novosibirsk

634050

Research Site, Tomsk

660022

Research Site, Krasnoyarsk

5265601

Research Site, Ramat Gan

06514-3434

Research Site, New Haven

02215

Research Site, Boston

CT9 4AN

Research Site, Kent

LE15WW

Research Site, Leicester

All Listed Sponsors
collaborator

Parexel

INDUSTRY

collaborator

Q2 Solutions

INDUSTRY

collaborator

PRA Health Sciences

INDUSTRY

collaborator

Covance

INDUSTRY

lead

AstraZeneca

INDUSTRY